Deltex Sponsoring Evidence-Based Clinical Event

Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and latest evidence relating to Goal-Directed Hemodynamic Therapy (GDHT). Speakers at the event will include UCL Professors Monty Mythen and Mervyn Singer, both leading experts in their respective fields.

The timing is particularly appropriate, given the recent publication of the landmark FEDORA study that has demonstrated the positive effect of using ODM technology to guide fluid and vasoactive drug interventions.

The event will take place at the Great Russell Suite, Montague Hotel, London, WC1B 5BJ

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    TopMedTalk Journal Review of FEDORA study

    The BJA recently published the FEDORA RCT of 420 patients. The study’s statistically significant results reinforce the UK’s NICE recommendation to use oesophageal Doppler monitor (ODM). Now, TopMedTalk, disseminator of medical news, has reviewed the paper in its Journal Club,

    Deltex Medical Group Plc

    Support for ODM from Largest Ever Intra-Op Haemodynamic RCT

    The British Journal of Anaesthesia (BJA) has published a new study, the largest ever positive Randomised Clinical Trial (RCT) on Goal-Directed Haemodynamic Therapy(GDHT) using Deltex Medical’s ODM system. The results demonstrate that even surgical patients considered to be at

    Deltex Medical Group Plc

    Deltex Medical reduces postoperative complications by 75 per cent

    Ewan Phillips, Deltex Medical’s Chief Executive, commented: “Complications after surgery are unpleasant, expensive to treat and reduce patients’ post-operative survival. The ability to eliminate over half of these is of huge value to both patients and

    Deltex Medical Group Plc

    How does the UK solve the innovation puzzle?

    The government should help SMEs to reward their advances with quicker mass adoption by the NHS, according to Andy Mears, Managing Director of Deltex Medical Group plc (LON:DEMG) Companies can seek grant funding or tax breaks ranging from R&D credits to the Enterprise Investment Scheme for risk

    Deltex Medical Group Plc

    Major US Hospital Adopts ODM Based on its Own Evidence

    Using data from 150 of its own patients, a “top ten” U.S. hospital is to adopt Deltex’s Oesophageal Doppler Monitoring (ODM) system. Ranked in the top ten hospitals in the USA, the University Teaching Hospital is a

    Deltex Medical Group Plc

    Deltex Medical Group PLC Major New US Hospital Account

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the addition of a major new hospital in the USA. The hospital is a University Teaching Hospital in our Mid-Atlantic sales

    Deltex Medical Group Plc

    Doppler Monitoring Papers in BJA’s Top 25 Influencers

    Last month saw World Anaesthesia Day and now this month we’re also celebrating the 25th anniversary of the Royal College of Anaesthetists, which received its Royal Charter as recently as 1992. TheBritish Journal of Anaesthesia has marked

    Deltex Medical Group Plc

    “Most exciting new thing in haemodynamics in over a decade”

    Interviewed about Deltex Medical Group’s new TrueVue system, Chief Exec Ewan Phillips talks about the product’s background. Specifically, he explains how the company is “changing the story” by adding best-in-class technologies to its high end oesophageal

    Deltex Medical Group Plc

    Deltex Medical Group plc New US Hospital Account

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the addition of a significant new hospital account in the USA. The new account is a 600 bed teaching hospital which

    Deltex Medical Group Plc

    Deltex Medical Group plc Release and First Sale of HD-ICG in France

    Deltex Medical Group plc (LON:DEMG), the global leader in oesophageal Doppler monitoring (“ODM”) today announced the release and first sales of its new High Definition Impedance Cardiography (HD-ICG) modality in France. The Company released the French language